Genentech, Inc.

Last covered conference date: October 14, 2008 @ 1:45 PM Pacific Time

Analyst Conference summaries and reports available:

[I am no longer summarizing Genentech conferences, but may post comments on occasion.]

Genentech Pipeline and Analyst Conference Summary [July 15, 2008]
FDA's Avastin for Breast Cancer Decision [February 28, 2008]
Genentech (DNA) Stalls, Points to Pipeline [January 14, 2008]
Rituxan and Zevalin, A Cautionary Tale [July 14, 2007 at New York Times, registration required]
Genentech's Pipeline [July 11, 2007]

Genentech (DNA) analyst conference summary q3 2008
Genentech (DNA) Q2 2008 analyst conference summary
Genentech Q1 2008 analyst conference summary
Genentech Q4 2007 conference summary
Q3 2008
Q2 2008
Q1 2008
Q4 2007
Genentech Q3 2007 conference summary
DNA conference summary
DNA conference summary

Q3 2007
Q2 2007
Q1 2007

 Q4 2006

Genentech uses genetic research to develop medicines. It is one of the earliest and most successful biotechnology pharmaceuticals companies. Its current drug portfolio includes Herceptin, Avastin, Rituxan, and Lucentis.

Genentech Web site:

main page
investor page

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but its possible. Before making or terminating an investment you should always verify any factual basis of your decision.